Hyperimmune plasma against COVID-19: Does it work or not? - 25/10/24
Highlights |
• | Transfusion of COVID-19 convalescent plasma (CCP) is safe with a low rate of adverse reactions. |
• | Early transfusion (within 5 days from symptom onset) of high-titer CCP convalescent plasma is effective in reducing hospitalization in COVID-19 outpatients. |
• | Transfusion of high-titer CCP within 8 days from symptom onset is associated with a mortality benefit in hospitalized COVID-19 patients. |
• | CCP is an effective therapeutic choice for immunocompromised COVID-19 patients. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.